問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2025-08-20

蔡宗翰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡宗翰

List

27Cases

2025-12-01 - 2033-05-05

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

2023-11-01 - 2028-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-02-03 - 2029-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Injectable frozen powder

Participate Sites
5Sites

Recruiting5Sites

2025-06-30 - 2032-05-01

Phase II

Not yet recruiting
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    ASP5541

Participate Sites
6Sites

Recruiting6Sites

2026-03-04 - 2034-03-11

Phase II/III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2024-06-30 - 2029-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-03-01 - 2028-06-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB